{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:33:55Z","timestamp":1791182035980,"version":"4.1.0"},"reference-count":31,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Kit is a membrane-bound tyrosine kinase and receptor for stem cell factor (SCF) with a crucial role in hematopoiesis. Mutations of KIT occur in almost half of patients with core-binding factor leukemias, in which they have been associated with worse outcome. Development of new compounds targeting Kit may therefore hold promise for therapy. We investigated the activity and mechanism of action of APcK110, a novel Kit inhibitor, in the mastocytosis cell line HMC1.2 (KITV560G and KITD816V), acute myeloid leukemia (AML) lines OCIM2 and OCI\/AML3 (both wild-type), and primary samples from patients with AML. We show that (a) APcK110 inhibits proliferation of the mastocytosis cell line HMC1.2 and the SCF-responsive cell line OCI\/AML3 in a dose-dependent manner; (b) APcK110 is a more potent inhibitor of OCI\/AML3 proliferation than the clinically used Kit inhibitors imatinib and dasatinib and at least as potent as cytarabine; (c) APcK110 inhibits the phosphorylation of Kit, Stat3, Stat5, and Akt in a dose-dependent fashion, showing activity of APcK110 on Kit and its downstream signaling pathways; (d) APcK110 induces apoptosis by cleavage of caspase-3 and poly(ADP-ribose) polymerase; and (e) APcK110 inhibits proliferation of primary AML blasts in a clonogenic assay but does not affect proliferation of normal colony-forming cells. Although APcK110 activity may partly depend on cytokine responsiveness (e.g., SCF) and not exclusively KIT mutation status, it remains a potent inhibitor of AML and mastocytosis cell lines and primary AML samples. APcK110 and similar compounds should be evaluated in clinical trials of patients with AML. [Cancer Res 2009;69(9):3910\u20137]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-0034","type":"journal-article","created":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T03:00:39Z","timestamp":1240369239000},"page":"3910-3917","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Kit Inhibitor APcK110 Induces Apoptosis and Inhibits Proliferation of Acute Myeloid Leukemia Cells"],"prefix":"10.1158","volume":"69","author":[{"given":"Stefan","family":"Faderl","sequence":"first","affiliation":[{"name":"1Leukemia and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Pal","sequence":"additional","affiliation":[{"name":"2Experimental Diagnostic Imaging, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Bornmann","sequence":"additional","affiliation":[{"name":"2Experimental Diagnostic Imaging, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Albitar","sequence":"additional","affiliation":[{"name":"3Quest Diagnostics Nichols Institute, San Juan Capistrano, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Maxwell","sequence":"additional","affiliation":[{"name":"2Experimental Diagnostic Imaging, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quin","family":"Van","sequence":"additional","affiliation":[{"name":"1Leukemia and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghong","family":"Peng","sequence":"additional","affiliation":[{"name":"2Experimental Diagnostic Imaging, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Harris","sequence":"additional","affiliation":[{"name":"1Leukemia and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Liu","sequence":"additional","affiliation":[{"name":"1Leukemia and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inbal","family":"Hazan-Halevy","sequence":"additional","affiliation":[{"name":"1Leukemia and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"1Leukemia and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[{"name":"1Leukemia and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2009,4,30]]},"reference":[{"key":"2022061701490198100_B1","doi-asserted-by":"crossref","unstructured":"Byrd JC, Mro\u0301zek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood\u20082002; 100: 4325\u201336.","DOI":"10.1182\/blood-2002-03-0772"},{"key":"2022061701490198100_B2","doi-asserted-by":"crossref","unstructured":"Marcucci G, Mro\u0301zek K, Ruppert AS, et al. Abnormal cytogenetics at date of morphologic complete remission predicts shorter overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B Study 8461. J Clin Oncol\u20082004; 22: 2410\u20138.","DOI":"10.1200\/JCO.2004.03.023"},{"key":"2022061701490198100_B3","doi-asserted-by":"crossref","unstructured":"Fro\u0308hling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood\u20082006; 108: 3280\u20138.","DOI":"10.1182\/blood-2006-04-014324"},{"key":"2022061701490198100_B4","doi-asserted-by":"crossref","unstructured":"Fro\u0308hling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol\u20082005; 23: 6285\u201394.","DOI":"10.1200\/JCO.2005.05.010"},{"key":"2022061701490198100_B5","doi-asserted-by":"crossref","unstructured":"Kitamura Y, Hirota S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci\u20082004; 61: 2924\u201331.","DOI":"10.1007\/s00018-004-4273-y"},{"key":"2022061701490198100_B6","doi-asserted-by":"crossref","unstructured":"Roskoski R, Jr. Structure and regulation of Kit protein-tyrosine kinase\u2014the stem cell factor receptor. Biochem Biophys Res Commun\u20082005; 338: 1307\u201315.","DOI":"10.1016\/j.bbrc.2005.09.150"},{"key":"2022061701490198100_B7","doi-asserted-by":"crossref","unstructured":"Ro\u0308nnstrand L. Signal transduction via the stem cell factor receptor\/c-Kit. Cell Mol Life Sci\u20082004; 61: 2535\u201348.","DOI":"10.1007\/s00018-004-4189-6"},{"key":"2022061701490198100_B8","doi-asserted-by":"crossref","unstructured":"Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A\u20081995; 92: 10560\u20134.","DOI":"10.1073\/pnas.92.23.10560"},{"key":"2022061701490198100_B9","unstructured":"Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res\u20082001; 61: 8118\u201321."},{"key":"2022061701490198100_B10","doi-asserted-by":"crossref","unstructured":"Kemmer K, Corless CL, Fletcher JA, et al. KIT mutations are common in testicular seminomas. Am J Pathol\u20082004; 164: 305\u201313.","DOI":"10.1016\/S0002-9440(10)63120-3"},{"key":"2022061701490198100_B11","doi-asserted-by":"crossref","unstructured":"Nanri T, Matsuno N, Kawakita T, et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia\u20082005; 19: 1361\u20136.","DOI":"10.1038\/sj.leu.2403803"},{"key":"2022061701490198100_B12","doi-asserted-by":"crossref","unstructured":"Du J, Schlenk RF, Corbacioglu A, et al. Detection of RAS, KIT and FLT3 gene mutations in t(8:21)-positive acute myeloid leukemia (AML): evaluation of the clinical relevance. Blood\u20082006; 108: 652a.","DOI":"10.1182\/blood.V108.11.2301.2301"},{"key":"2022061701490198100_B13","doi-asserted-by":"crossref","unstructured":"Du J, Schlenk RF, Corbacioglu A, et al. RAS, KIT and FLT3 gene mutations in inv(16)\/t(16;16)-positive acute myeloid leukemia (AML): incidence and relevance on clinical outcome. Blood\u20082006; 108: 653a.","DOI":"10.1182\/blood.V108.11.2303.2303"},{"key":"2022061701490198100_B14","doi-asserted-by":"crossref","unstructured":"Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood\u20082006; 107: 3463\u20138.","DOI":"10.1182\/blood-2005-09-3640"},{"key":"2022061701490198100_B15","doi-asserted-by":"crossref","unstructured":"Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML-ETO-positive AML are associated with impaired event-free and overall survival. Blood\u20082006; 107: 1791\u20139.","DOI":"10.1182\/blood-2005-04-1466"},{"key":"2022061701490198100_B16","doi-asserted-by":"crossref","unstructured":"Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8; 21): a Cancer and Leukemia Group B Study. J Clin Oncol\u20082006; 107: 3904\u201311.","DOI":"10.1200\/JCO.2006.06.9500"},{"key":"2022061701490198100_B17","unstructured":"Maxwell DS, Pal A, Peng Z, et al. Structure-based drug design of c-Kit inhibitors for use in the treatment of acute myeloid leukemia. Blood\u20082006; 106: 540a."},{"key":"2022061701490198100_B18","doi-asserted-by":"crossref","unstructured":"Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res\u20081988; 12: 345\u201355.","DOI":"10.1016\/0145-2126(88)90050-1"},{"key":"2022061701490198100_B19","doi-asserted-by":"crossref","unstructured":"Estrov Z, Manna SK, Harris D, et al. Phenylarsine oxide blocks interleukin-1-induced activation of the nuclear transcription factor NF-\u03baB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood\u20081999; 94: 2844\u201353.","DOI":"10.1182\/blood.V94.8.2844.420k43_2844_2853"},{"key":"2022061701490198100_B20","doi-asserted-by":"crossref","unstructured":"Tuyt LML, Bregman K, Lummen C, et al. Differential binding activity of the transcription factor LIL-STAT in immature and differentiated normal and leukemia myeloid cells. Blood\u20081998; 92: 1364\u201373.","DOI":"10.1182\/blood.V92.4.1364.416k34_1364_1373"},{"key":"2022061701490198100_B21","doi-asserted-by":"crossref","unstructured":"Minden MD, Buick RN, McCulloch EA. Separation of blast cells and T lymphocyte progenitors in the blood of patients with acute myeloblastic leukemia. Blood\u20081979; 54: 186\u201395.","DOI":"10.1182\/blood.V54.1.186.186"},{"key":"2022061701490198100_B22","doi-asserted-by":"crossref","unstructured":"Estrov Z, Grunberger T, Dube ID, et al. Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. N Engl J Med\u20081986; 315: 538\u201342.","DOI":"10.1056\/NEJM198608283150902"},{"key":"2022061701490198100_B23","doi-asserted-by":"crossref","unstructured":"Radmacher MD, Marcucci G, Ruppert AS, et al. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood\u20082006; 108: 1677\u201383.","DOI":"10.1182\/blood-2006-02-005538"},{"key":"2022061701490198100_B24","unstructured":"Advani AS. C-kit as a target in the treatment of acute myelogenous leukemia. Curr Hematol Rep\u20082005; 4: 51\u20138."},{"key":"2022061701490198100_B25","doi-asserted-by":"crossref","unstructured":"Lu C, Hassan HT. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells. Leuk Res\u20082006; 30: 296\u2013302.","DOI":"10.1016\/j.leukres.2005.06.026"},{"key":"2022061701490198100_B26","doi-asserted-by":"crossref","unstructured":"Heidel F, Cortes J, Ru\u0308cker FG, et al. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-C and imatinib. Cancer\u20082007; 109: 907\u201314.","DOI":"10.1002\/cncr.22471"},{"key":"2022061701490198100_B27","doi-asserted-by":"crossref","unstructured":"Cairoli R, Beghini A, Morello E, et al. Imatinib mesylate in the treatment of core binding factor leukemias with KIT mutations: a report of three cases. Leuk Res\u20082005; 29: 397\u2013400.","DOI":"10.1016\/j.leukres.2004.10.005"},{"key":"2022061701490198100_B28","doi-asserted-by":"crossref","unstructured":"Nanri T, Matsuno N, Kawakita T, et al. Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation. Leukemia\u20082005; 19: 1673\u20135.","DOI":"10.1038\/sj.leu.2403889"},{"key":"2022061701490198100_B29","doi-asserted-by":"crossref","unstructured":"Schnittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res\u20082006; 66: 473\u201381.","DOI":"10.1158\/0008-5472.CAN-05-2050"},{"key":"2022061701490198100_B30","unstructured":"Fabbro D, Ruetz S, Bodis S, et al. PKC412: a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des\u20082000; 15: 17\u201328."},{"key":"2022061701490198100_B31","doi-asserted-by":"crossref","unstructured":"Gotlib J, Berube\u0301 C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816 KIT mutation. Blood\u20082005; 106: 2865\u201370.","DOI":"10.1182\/blood-2005-04-1568"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/9\/3910\/2623964\/3910.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/9\/3910\/2623964\/3910.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T09:21:56Z","timestamp":1655457716000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/69\/9\/3910\/553339\/Kit-Inhibitor-APcK110-Induces-Apoptosis-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,30]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2009,4,30]]},"published-print":{"date-parts":[[2009,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-0034","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,30]]}}}